Trump FDA nominee played key role in overhaul of childhood vaccine policy

Heidi Overton, President Donald Trump's nominee to lead the Food and Drug Administration, played a central role in shaping the Trump administration's effort to revise childhood vaccination policies. According to a senior administration official and three individuals familiar with the process, Overton, who previously worked as an aide on the president’s Domestic Policy Council, helped edit and craft the scientific rationale behind reducing the Centers for Disease Control and Prevention's recommended number of vaccines for children from 17 to 11. This change took effect in January. Overton’s influence extended beyond drafting the justification. She convened meetings with key figures within the Trump administration, including Health Secretary Robert F. Kennedy Jr., then-FDA Commissioner Marty Makary, Medicare and Medicaid overseer Mehmet Oz, NIH director Jay Bhattacharya, and HHS official Stefanie Spear, a close associate of Kennedy. These discussions aimed to build consensus across health agencies regarding the narrower list of recommended vaccines. During her Senate confirmation hearing, Overton asserted that all vaccines currently available in the United States are safe and effective according to the FDA. However, her involvement in the policy shift became clearer later in 2025, as she worked to align various health agencies around the revised vaccination schedule. Some within the administration suggested that Overton’s contributions reflected the broader dynamics of White House policymaking rather than personal motivation. One administration official noted that there might be a misunderstanding about Overton’s role, emphasizing that the White House operates in a top-down manner. In July 2025, The Atlantic reported that Overton had participated in creating an early draft of the childhood vaccine recommendations. At the time, Kennedy reportedly considered endorsing Denmark’s vaccine schedule, which includes 10 recommended vaccinations for children. However, a planned press conference by Kennedy in December was abruptly canceled due to concerns raised by HHS lawyers about insufficient evidence supporting the proposal and potential legal challenges. On January 5, former Health Deputy Secretary and acting CDC Director Jim O’Neill signed a decision memo adopting the revised childhood immunization schedule. This revision was based on assessments by Høeg, the acting director of the FDA’s Center for Drug Evaluation and Research, and Martin Kulldorff, an HHS aide. The American Academy of Pediatrics filed a lawsuit challenging the revised schedule, leading a federal judge to place it on hold in March. Separately, former FDA commissioners criticized the Trump administration's handling of the agency, describing the mass layoffs known as DOGE as one of the worst disasters in American history. Robert Califf, who served as FDA commissioner under Presidents Obama and Biden, stated that the cuts of 3,500 workers were followed by a larger exodus under former FDA Commissioner Marty Makary, who resigned in May. Califf emphasized that restoring the agency’s institutional knowledge would take years. Former FDA Commissioner Scott Gottlieb and Acting Commissioner Ned Sharpless echoed these sentiments, highlighting the loss of experienced personnel and the need for new leadership to rebuild the agency. They expressed cautious optimism about current leadership, including acting commissioner Kyle Diamantas and policy lead Grace Graham, whom they believe are steering the FDA toward more stable operations. Despite this progress, the former officials urged Overton, if confirmed, to prioritize protecting the agency’s workforce from political interference and to focus on rebuilding trust in federal health agencies. They also cautioned against continued skepticism surrounding vaccines, particularly given the actions of Health Secretary Robert F. Kennedy Jr., whose efforts to reform vaccine policy have drawn criticism for potentially undermining public confidence.